ClinicalTrials.gg

Program

LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010

Its studies are mostly in Multiple Myeloma, led by Kelonia Therapeutics.

Furthest: phase 1, since Jul 2, 20251 company-led study, 1 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kelonia Therapeutics11 open or runningphase 1since Jul 2, 2025Jul 2, 2025Mar 2027phase 1 · NCT07075185

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 2, 2025First study: phase 1 study in Multiple MyelomaFirst studyNCT07075185 · 70 planned · United States, Australia

Ahead

  1. Mar 2027Primary completion: phase 1 study in Multiple MyelomaNCT07075185

TargetBeta

“A gene therapy agent composed of a replication-incompetent, self-inactivating lentiviral vector (LVV) expressing a modified vesicular stomatitis virus (VSV) glycoprotein fusogen and an anti-CD3 single chain variable fragment (scFv), and encapsulating a transgene encoding for a chimeric antigen recep”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 38
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
cizutamigruleUCBphase 25
vonsetamigruleRegeneron Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07075185Multiple Myeloma · United States, Australia1RecruitingMar 202770

How it is read

Names in the registry

  • “KLN-1010”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.